Pericarditis Market
Pericarditis Market is segmented By Diagnosis and Treatment (Diagnosis, Treatment, Medication, Surgical Treatment), By Application(Acute Pericarditis, Chronic Pericarditis, Recurrent Pericarditis), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030.
Pericarditis Market size was valued US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of 3.8% during the forecast period (2023-2030). The pericardium, a slender, two-layered sac that encircles the heart, becomes inflamed, and this condition is known as pericarditis. In the chest wall, the pericardium aids in keeping the heart in position. Viral infections account for 80 to 90% of pericarditis cases, though the cause of most cases is unknown. Less than three weeks are usually its average duration. Pericarditis typically heals by itself. However, some treatments are available to shorten the severity of the condition and avoid recurrences.
Pericarditis Market - Strategic Insights
|
Metrics |
Details |
|
Market CAGR |
3.8% |
|
Segments Covered |
By Type, By Diagnosis & Treatment, By Treatment, By End-User, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click here
Market Dynamics
The increasing prevalence of cardiovascular diseases, technological advancement in monitoring devices to detect pericarditis, and increasing clinical trials for treating pericarditis are the factors driving the market in the forecast period.
Increasing clinical trials for treating pericarditis is expected to drive market growth.
Kiniksa Pharmaceuticals (UK), Ltd. conducted a phase- III multicenter, double-blind, event-driven, randomized-withdrawal trial of patients with acute symptoms of recurrent pericarditis and systemic inflammation (as assessed on a patient-reported scale). Patients who presented with recurrent pericarditis while on standard therapy were enrolled in a 12-week period and background medications on rilonacept were stopped. Therefore, rilonacept resulted in faster resolution of recurrent pericarditis episodes and a significantly lower risk of recurrence than placebo in patients with recurrent pericarditis. Therefore, increasing clinical trials by the market players for treating pericarditis is projected to drive market growth in the forecast period.
Side effects associated with corticosteroid drugs are expected to hamper market growth.
Although pericarditis frequently manifests as benign and self-limiting, recurrences can occur. Colchicine is added to aspirin and nonsteroidal anti-inflammatory drugs (ASA/NSAIDs) as the first line of treatment. High doses of steroids, in particular, have been linked to a higher recurrence rate. Prednisone patients receiving high doses experienced more severe side effects than those receiving lower doses. A vertebral collapse, severe osteoporosis requiring medical attention, and severe cushingoid syndrome in other cases were among the severe side effects reported. Thus, from the above factors, the market is expected to be hampered in the forecast period.
COVID-19 Impact Analysis
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) poses an unprecedented challenge to the global healthcare community. SARS-CoV-2 infection is possible in cardiovascular tissues or cells expressing ACE2, including lung cells. COVID-19 has been linked to cardiovascular complications such as myocarditis, pericardial effusion, and pericarditis. Pericardial effusion is common in hospitalized COVID-19 patients but is rarely due to acute pericarditis. It has been linked to myocardial dysfunction and mortality. The outcome can be predicted using a limited echocardiographic examination that measures left ventricular ejection fraction, tricuspid annular plane systolic excursion, and checks for pericardial effusion. Moreover, following a prospectively predefined protocol, consecutive COVID-19 patients underwent clinical and echocardiographic examination within 48 hours, regardless of the clinical indication. Therefore, the market got affected moderately by the above factors, and it is expected to improve in the forecast period.
Segment Analysis
Medications sub-segment is expected to hold the largest market share in pericarditis
The medications sub-segment accounted for the largest market share in 2021. The segment is further sub-segmented into salicylates, nonsteroidal anti-inflammatory drugs, anti-inflammatory drugs, and corticosteroids. The first line of treatment for acute and recurrent pericarditis is nonsteroidal anti-inflammatory drugs (NSAIDs). The three most popular NSAIDs are ibuprofen, aspirin, and indomethacin. Research has concentrated on NSAIDs' effectiveness and common adverse effects. Moreover, NSAIDs (including aspirin) reduce inflammation and relieve pain in most patients. Thus, from the above-mentioned factors, the market segment accounted for the largest market share in the forecast period.
Geographical Analysis
North America region holds the largest market share in the global pericarditis market
North America region accounted for the largest market share in 2021. The increasing prevalence of cardiovascular diseases, the rising geriatric population, increasing investments in research and development, and increasing clinical trials in the region are the factors the market is expected to drive in the forecast period. For instance, according to the Centers for Disease Control and Prevention, coronary artery disease, which affects the blood flow to the heart, is the most prevalent form of heart disease in the U.S. A heart attack may be brought on by decreased blood flow. By 2020, they are killing 382,820 people. 7.2% or 20.1 million adults aged 20 and over have CAD. In 2020, adults under 65 will account for about 2 in 10 deaths from CAD. Therefore, there is increased demand for diagnostic and drugs in the region. Thus, from the above factors, the North America region accounted for the largest market share in the forecast period.
Competitive Landscape
Major key players in the pericarditis market are Bayer AG, Johnson & Johnson Services Inc., Pfizer Inc., Takeda Pharmaceutical Co. Ltd., Reckitt Benckiser Group Plc, Novartis International AG, Allergan plc, Merck & Co., Inc., PerkinElmer, Inc, Fujifilm Holdings Corporation, Sanofi and AstraZeneca Plc.
Pfizer, Inc.:
Overview:
Pfizer Inc. is an American pharmaceutical MNC. The company develops and manufactures medicines and vaccines for various medical disciplines, including immunology, oncology, cardiology, endocrinology, neurology and other therapeutic areas. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. Pfizer Limited has over 150 products across 15 therapeutic areas. Eucrisa, a novel non-steroidal topical phosphodiesterase-4 (PDE-4) inhibitor, was acquired by Pfizer through the acquisition of Anacor Pharmaceuticals, Inc. It is the first prescription treatment for atopic dermatitis to be approved by the FDA in more than ten years. It sells its vaccines to the federal government and the Centers for Disease Control and Prevention in the U.S. (CDC).
Product Portfolio:
Motrin (Ibuprofen) Tablets: Motrin (Ibuprofen) is an over-the-counter drug used to treat Pericarditis pain.
The global pericarditis market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.